St. Louis Monetary Planners Asset Administration, LLC initiated a brand new stake in AbbVie (ABBV -1.01%), buying 14,630 shares for an estimated $3.39 million in Q3 2025.
What occurred
Based on a Securities and Alternate Fee (SEC) submitting dated October 02, 2025, St. Louis Monetary Planners Asset Administration, LLC disclosed a brand new place in AbbVie(ABBV -1.01%). The agency acquired 14,630 shares, bringing its quarter-end holding to $3.39 million. The place accounted for two.1842% of the fund’s $155,093,822 in reportable U.S. fairness belongings throughout 37 positions.
What else to know
This new place represents 2.2% of the fund’s 13F belongings as of 2025-09-30
Prime holdings after the submitting:
- NYSEMKT:BIL: $36.73 million (23.7% of AUM as of 2025-09-30)
- NYSEMKT:TFLO: $17.27 million (11.1% of AUM as of 2025-09-30)
- NASDAQ:BSCP: $10.45 million (6.7% of AUM as of 2025-09-30)
- NASDAQ:PLTR: $9.23 million (6.0% of AUM as of 2025-09-30)
- NASDAQ:AVGO: $5.16 million (3.3% of AUM as of 2025-09-30)
As of October 1, 2025, AbbVie shares had been priced at $244.38, up 24.08% over the previous 12 months and outperforming the S&P 500 by 11.71 proportion factors
Firm Overview
MetricValueRevenue (TTM)$58.33 billionNet Earnings (TTM)$3.77 billionDividend Yield2.72percentWorth (as of market shut 2025-10-01)$244.38
Firm Snapshot
AbbVie generates income primarily by the event, manufacturing, and sale of branded prescribed drugs, together with key merchandise similar to HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, and BOTOX Therapeutic.
The corporate operates a research-driven enterprise mannequin, specializing in innovation and the enlargement of its drug portfolio throughout a number of therapeutic areas.
AbbVie serves a world buyer base, together with healthcare suppliers, hospitals, and authorities companies, with a deal with superior therapies for autoimmune illnesses, oncology, and specialty care.
AbbVie discovers, develops, manufactures, and sells prescribed drugs worldwide, together with merchandise for autoimmune illnesses, oncology, and different situations. Its diversified portfolio and dedication to analysis help its aggressive place within the healthcare sector.
Silly take
AbbVie is without doubt one of the high pharmaceutical corporations available on the market proper now, regardless of its comparatively current lack of patent for Humira, which was a blockbuster drug for the corporate. Regardless of this, its dividend stays sturdy and its drug pipeline strong. A number of new medicine are within the works for fields like immunology, oncology, and aesthetics.
Since its acquisition of Allergan, maker of Botox, AbbVie has been burdened with the next debt load than typical, however equally excessive money flows have stored steadiness sheets wholesome. Nevertheless, a dependence on just a few profitable medicine does create critical threat ought to regulation or pricing pressures grow to be a extra important issue within the close to time period. Greater rates of interest may additionally grow to be an issue, ought to the corporate have to refinance the debt it acquired in 2019 with the acquisition of Allergan.
Even so, AbbVie continues to be a strong Wall Avenue Purchase suggestion, with 5 Sturdy Buys and 13 Buys for October, in addition to 9 Maintain suggestions. It continues to beat on evaluation estimated EPS this 12 months, exhibiting that it could actually, actually, pivot regardless of the lack of a significant revenue stream.
Glossary
Stake: The possession or funding a agency holds in a selected firm or asset.
Reportable AUM: Belongings below administration that have to be disclosed in regulatory filings, such because the SEC’s 13F report.
13F belongings: U.S. fairness securities managed by institutional funding managers, reported quarterly to the SEC on Type 13F.
Prime holdings: The biggest investments in a fund’s portfolio, usually ranked by market worth.
Dividend yield: Annual dividends paid by an organization as a proportion of its present share value.
Outperforming: Reaching the next return than a benchmark index or comparable funding.
TTM: The 12-month interval ending with the latest quarterly report.
Branded prescribed drugs: Pharmaceuticals offered below a trademarked model title, versus generic variations.
Autoimmune illnesses: Medical situations the place the immune system mistakenly assaults the physique’s personal tissues.
Oncology: The department of medication centered on the prognosis and therapy of most cancers.
Kristi Waterworth has no place in any of the shares talked about. The Motley Idiot has positions in and recommends AbbVie and Palantir Applied sciences. The Motley Idiot recommends Broadcom. The Motley Idiot has a disclosure coverage.
